Australians with prostate and breast cancer now have affordable access to affordable new and expanded medicines under the ...

Her team recently developed a small nanocarrier that actively delivers a poly (ADP-ribose) polymerase (PARP) inhibitor and a ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Fig 2. Approximately week 90; 7 weeks into second round of gemcitabine/docetaxel treatment. Fig 3. Approximately week 109; roughly 1 week before starting niraparib (poly(ADP-ribose) polymerase ...

GSK has reported that the double-blind, randomised Phase III FIRST-ENGOT-OV44 trial of Zejula (niraparib) and Jemperli ...

Pamiparib is under clinical development by BeiGene and currently in Phase II for Glioblastoma Multiforme (GBM).

Cao's team studied multiple human prostate cancer cell lines and discovered that the EZH2 protein directly methylates and regulates the activity of poly (ADP–ribose) polymerase-1 (PARP1), an ...

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has announced funding for a new project ...

The safety and tolerability profile was generally consistent with the known safety profiles of the individual agents, GSK said. Zejula is an oral, once-daily poly-ADP ribose polymerase inhibitor ...